Want to join the conversation?
$MRK said that it's planning to submit a supplemental Biologics License Application (sBLA) to the U.S. FDA for KEYTRUDA (pembrolizumab) by the end of 2015 based on the findings from KEYNOTE-010 clinical trial. The company is also intending to submit a Marketing Authorization Application to the European Medicines Agency in early 2016.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.